Deruxtecan – Talk Bio

Daiichi and Merck’s Lung Cancer ADC Achieves 48% Response Rate in Pivotal Trial

2 days ago talkbio0Tagged Accelerated, Antibody-Drug Conjugates, Approved, Breakthrough Therapy, CD276 gene, Co., Daiichi, Deruxtecan, Frequency of Responses, IDeate-Lung01, Identifier, ifinatamab, Overall Survival, Progression-Free Survival, Sankyo, Small cell carcinoma of lung, therapeutic autologous dendritic cells, United States Food and Drug Administration

Daiichi Sankyo; Merck & Co.; ifinatamab deruxtecan; I-DXd; B7-H3; antibody-drug conjugate; ADC; small cell lung cancer; SCLC; IDeate-Lung01; objective response rate; accelerated approval; progression-free survival; overall survival; FDA Breakthrough Therapy Designation

Merck, Daiichi Sankyo Withdraw FDA Application for HER3-Targeting ADC After Survival Endpoint Miss

3 months ago talkbio0Tagged Application procedure, Clinical Trials, Daiichi, Deruxtecan, HER3, Merck, Non-Small Cell Lung Carcinoma, Overall Survival, patritumab, Sankyo, therapeutic autologous dendritic cells, United States Food and Drug Administration, Withdraw (activity)

Merck; Daiichi Sankyo; patritumab deruxtecan; HER3 ADC; FDA application; non-small cell lung cancer; clinical trial; overall survival; application withdrawal

Daiichi Sankyo and Merck Achieve Phase III Success with HER3-Targeted ADC in Lung Cancer

12 months ago talkbio0Tagged Co., Daiichi, Deruxtecan, HER3-Targeted, HERTHENA-Lung02, Non-Small Cell Lung Carcinoma, patritumab, Phase 3 Clinical Trials, Sankyo, therapeutic autologous dendritic cells

Patritumab deruxtecan, HER3-targeted ADC, Non-small cell lung cancer (NSCLC), Phase III trial, HERTHENA-Lung02, Daiichi Sankyo, Merck & Co.

Enhertu Demonstrates Promising Efficacy in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases

12 months ago talkbio0Tagged Deruxtecan, Enhertu, Frequency of Responses, HER2-positive metastatic breast cancer, Metastatic malignant neoplasm to brain, Progression-Free Survival, trastuzumab

Enhertu, Trastuzumab Deruxtecan, HER2-positive metastatic breast cancer, brain metastases, progression-free survival, objective response rate.

WCLC24: Merck & Daiichi Sankyo’s ADC Shows Promising Results in Small Cell Lung Cancer

1 year ago talkbio0Tagged Antibody-Drug Conjugates, Co., Daiichi, Deruxtecan, DXd, ifinatamab, Sankyo, Small cell carcinoma of lung, Technology, therapeutic autologous dendritic cells, WCLC24

WCLC24, Merck & Co., Daiichi Sankyo, ADC (Antibody Drug Conjugate), SCLC (Small Cell Lung Cancer), Ifinatamab Deruxtecan, DXd ADC Technology

Promising Phase 2 Results for Ifinatamab Deruxtecan in Small Cell Lung Cancer

1 year ago talkbio0Tagged Cell Lung Cancer, Daiichi, Deruxtecan, ifinatamab, Phase 2 trial, Sankyo, Small, Technology, therapeutic autologous dendritic cells

Ifinatamab Deruxtecan, Small Cell Lung Cancer, Phase 2 Trial, ADC Technology, Daiichi Sankyo, Merck

AstraZeneca and Gilead Explore TROP2 ADCs in Lung Cancer, Seeking Pathways to Approval

1 year ago talkbio0Tagged ADCs, AstraZeneca, Datopotamab, Deruxtecan, Malignant neoplasm of lung, Non-Small Cell Lung Carcinoma, TACSTD2 gene, Trodelvy

TROP2 ADCs, Lung Cancer, AstraZeneca, Gilead, Datopotamab Deruxtecan, Trodelvy, Non-Small Cell Lung Cancer (NSCLC)

Merck and Daiichi Sankyo’s ADC Pact Hits Regulatory Setback in FDA Rejection

1 year ago talkbio0Tagged Antibody-Drug Conjugates, Daiichi, Deruxtecan, HER3 protein, Merck, Non-Small Cell Lung Carcinoma, patritumab, Regulatory Setback, Rejection (Psychology), Sankyo, United States Food and Drug Administration

Merck, Daiichi Sankyo, Antibody-Drug Conjugate (ADC), Patritumab Deruxtecan, FDA Rejection, Regulatory Setback, HER3 Protein, Non-Small Cell Lung Cancer (NSCLC)